Standard and Intensive Glucose Control Strategies Lead to Similar Survival Rates Among Diabetics

In a 6-year follow-up analysis of the ADVANCE trial, there were no significant differences in all-cause mortality or major macrovascular events (a composite of nonfatal myocardial infarction, nonfatal stroke, or death from any cardiovascular cause) between intensive-glucose-control and standard-glucose-control groups. However, the intensive-glucose-control group (with a target HbA1c of <6.5%) experienced a 46% decreased risk of ESRD compared to the standard-glucose-control group. The studyof 11,140 type 2 diabetics with ≥1 additional cardiovascular risk factor was published in the New England Journal of Medicine.